Best True Health
Welcome at

weight lossA low glycemic index (GI), low calorie diet with moderate amounts of carbohydrates is more effective for controlling hunger, and improving weight loss and insulin sensitivity than a low-fat, high GI diet.

Obesity is one of the most significant health concerns worldwide and is related to health issues such as hypertension, type 2 diabetes, cardiovascular disease, and some cancers. Low-glycemic index (GI) diets have shown to have beneficial effects in many chronic conditions such as these, but their impact on weight loss, satiety and inflammation are still somewhat inconclusive.

In a new study published online in the American Journal of Clinical Nutrition, researchers compared the effects of 3 diets on weight loss, satiety, inflammation and other metabolic markers. The randomized controlled study included 122 overweight or obese men and women aged 30 to 60 years. During the study period of 6 months, participants were randomly assigned to one of 3 isocaloric, energy-restricted diets: 1) a moderate carbohydrate and high-GI diet (HGI), 2) a moderate-carbohydrate and low-GI-Low Fat diet (LGI), 3) a low-fat and high-GI diet (LF) patterned after the American Heart Association Diet.

Reductions in BMI were greater in the Low GI group than the LF by week 16 and at the completion of the study. Measurements of insulin sensitivity, fasting insulin and beta-cell function were all significantly better in the LGI group than the LF group. Although the differences in the 3 groups didn’t reach statistical significance, there was a tendency for a greater improvement with a low-GI diet with respect to hunger, satiety, lipid profiles and other inflammatory and metabolic markers.

The results of this study showed that a low-calorie low-GI diet with moderate amounts of carbohydrates is more effective than a high-GI low-fat diet at decreasing body weight and improving markers of insulin metabolism.

Source:
Martí Juanola-Falgarona et al. Am J Clin Nutr June 2014. doi:10.3945/ajcn.113.081216.

LungRespiratory infectious conditions place a substantial health and economic burden on society. The economic impact of colds has been estimated to be $40 billion dollars in the USA annually. Recent systematic reviews have reported a positive, although modest, effect of probiotics in terms of preventing common cold symptoms. The recent systematic review further evaluated the effect of probiotics, specifically Lactobacillus and Bifidobacterium strains, on the duration of acute respiratory infections in otherwise healthy children and adults.

In the latest review, twenty randomised controlled trials (RCT) were included, of which twelve were considered to have a low risk of bias. The duration of probiotic treatment ranged from 3 weeks to 7 months, although the majority of trials were carried out for approximately 3 months over the winter months.

The meta-analysis revealed significantly fewer numbers of days of illness per person, shorter illness episodes by almost a day, and fewer numbers of days absent from day care/school/work in participants who received a probiotic intervention than in those who had taken a placebo.

In conclusion, this systematic review provides evidence from good-quality RCT that adding probiotics to diet helps reduce the duration of respiratory illness episodes in otherwise healthy children and adults and offers a viable cost-saving option in improving quality of life.

Source:
Sarah King et al; Br J Nutr. 2014 Apr 29:1-14

An analysis of 70 trials reveals that omega-3 supplementation may be as effective at reducing blood pressure as other lifestyle intervention.

Nearly 4 out of 10 Australian adults have elevated blood pressure, which is linked to an increased risk of strokes, coronary heart disease, and total mortality.  A recent metaanalysis published in the American Journal of Hypertension analyzed 70 RCT trials to determine the effect of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on blood pressure.

Weighted differences were used to separate individuals into an EPA+DHA group and a placebo group. All of the studies combined resulted in a 1.52 mm Hg reduction in systolic blood pressure and a 0.99 mm Hg reduction in diastolic blood pressure for the EPA+DHA group over the placebo group.

Additional data was used to further separate these into subgroups for additional analysis. This revealed even stronger effects of EPA+DHA, where a 4.51 mm Hg reduction in systolic blood pressure and a 3.05 mm Hg reduction in diastolic blood pressure were observed among untreated hypertensive subjects. In this subgroup, EPA+DHA treatment was as effective, or more effective, at lowering blood pressure than other lifestyle-intervention including increasing physical activity and restricting alcohol and sodium.

These results continue to build on prior evidence showing that omega-3 fatty acids may play a role in helping individuals control their blood pressure. One of the authors, Dominik Alexander, PhD, noted that “when measuring blood pressure, even small reductions can have a significant clinical impact.” A 2 mm Hg reduction in blood pressure reduces stroke mortality by 6%, coronary heart disease mortality by 4%, and total mortality by 3%.

Overall, available evidence from randomised controlled trials (RCT) indicates that provision of EPA+DHA reduces systolic blood pressure, while provision of ≥2 grams reduces diastolic blood pressure.

Source:
Miller, P.E. et al. Am J Hypertens. 2014 Mar 6. [Epub ahead of print] PMID:24610882

 

salmon 2

LemonResults from a new meta-analysis indicate an association between improved survival among women with breast cancer who have a higher intake of vitamin C from supplements or food.

The association between dietary vitamin C intake and breast cancer survival is inconsistent and few studies have specifically examined vitamin C supplement use among women with breast cancer. In a new study published online in the European Journal of Cancer, Swedish researchers summarized results from prospective studies to determine whether there is an association between vitamin C intakes and the risk of breast cancer mortality.

The current meta-analysis identified ten studies that included 17,696 women who were diagnosed with breast cancer. The studies examined the effect of dietary vitamin C intake or supplementing with vitamin C following breast cancer diagnosis.

When the studies that reported the effects of vitamin C supplements were evaluated, their use was associated with a 19% lower risk of total mortality and a 15% lower risk of dying from breast cancer in comparison with no use. When analyzing vitamin C intake from foods, researchers observed that for every 100mg per day increase in dietary vitamin C there was 27% decrease in total mortality and 22% decrease in breast cancer-specific mortality.

Results from this meta-analysis indicate that vitamin C supplement use after breast cancer diagnosis is associated with a reduction in total mortality and breast cancer-specific mortality. More studies on post diagnosis supplementation should be conducted to confirm these results and further our understanding of how their use during radiation or chemotherapy may influence breast cancer outcomes.

Source:
Holly R. Harris et al (May 2014), European Journal of Cancer, Vol.50 (7):1223–1231

SunshineA new meta-analysis reveals that higher Vitamin D levels are associated with significantly reduced mortality in patients with colorectal and breast cancer.

Breast cancer (BC) and colorectal cancer (CRC) are two of the most common causes of cancer death worldwide. These cancers share many of the same risk factors which include smoking, physical inactivity, poor diet, excessive alcohol consumption and obesity. The results of several studies have suggested that low vitamin D levels may be a potential risk factor for many cancers, including BC and CRC.

In a recent study published in the European Journal of Cancer, researchers summarized the evidence regarding a potential protective role of high Vitamin D levels with cancer mortality, and specifically among breast cancer and colorectal cancer patients.

The comprehensive literature search included studies which analyzed the association of vitamin D with suvival in breast cancer and colorectal cancer patients. The review included five studies of colorectal cancer patients (n=2,330), and five studies of breast cancer patients (n=4,413). The studies all compared mortality across two to five categories of vitamin D levels.

Among colorectal cancer patients, when compared to the category of lowest vitamin D, the group with the highest vitamin D levels had a 29% decreased risk of overall cancer mortality, and a 35% decreased mortality risk of CRC specifically. Comparing high to low vitamin D levels among breast cancer patients revealed a 38% and 42% reduction of overall cancer and BC mortality respectively.

These results showed that higher Vitamin D levels (>75nmol/L or 30 ng/dl) were associated with significantly reduced mortality in patients with colorectal and breast cancer. Randomised controlled trials are needed to evaluate whether vitamin D supplementation can improve survival in colorectal and breast cancer patients with low vitamin D status (25(OH)D<50nmol/L) at diagnosis and before treatment

Source:
Maalmi H. et al. Eur J Cancer. 2014 Feb 27. pii: S0959-8049(14)00124-5.

Research on omega-3 fatty acid levels in women during late pregnancy reveals a connection between low omega-3 intake during pregnancy and higher risk of postpartum depression.

Postpartum depression is a relatively common disorder that can lead to unhealthy early mother-infant interaction and potentially poor early childhood development. It is estimated that the disorder may affect as many as 10-15% of women in the first three months after birth. Several previous studies have looked at the possible connection between seafood intake and the incidence of postpartum depression.

In a study published online in PLos One, researchers sought to determine whether a low maternal omega-3 index in late pregnancy was associated with higher levels of postpartum depressive symptoms. The omega-3 index is a measurement of the omega-3 fats EPA and DHA in red blood cells, expressed as a percentage of total fatty acids.

The study group included 72 Norwegian women who were pregnant between November 2009 and June 2011. At 28 weeks of pregnancy, blood samples were taken from the mothers to determine the fatty acids status. At the well-baby check-up 3 months postpartum, a regional version of the Edinburgh Postnatal Depression Scale (EPDS) was used to determine the level of depressive symptoms in the mothers.

The women with a lower omega-3 index had a higher level of depressive symptoms three months after pregnancy. When analyzing percentage of DHA alone, the association was even more significant. In addition to the omega-3 index and DHA content, other measures such as the omega-3/omega-6 ratio were also inversely correlated to higher depressive symptoms. The reported dietary and supplemental intake of fish was highly correlated to the measured omega-3 index.

Since a low omega-3 index during pregnancy may be associated with a higher rate of depression symptoms after childbirth, increasing seafood or omega-3 supplement intake during and after pregnancy should be encouraged, especially in those that eat little to no seafood.

The researchers also suggest that larger and more powerful intervention studies should be completed, since there are currently no established reference values for fatty acid status in pregnant or lactating women.

Source:
Markhus MW et al. (2013). PLoS ONE 8(7): e67617.

pregnant

salmonThe results of a new meta-analysis shows that long-term supplementation with omega-3s reduce blood markers of inflammation and may reduce the risk of chronic inflammatory-related diseases.

Inflammation is known to play a role in numerous chronic diseases such as diabetes, cardiovascular disease (CVD), obesity-related diseases, rheumatoid arthritis and other autoimmune diseases.  Omega-3 fatty acids have often been linked to providing benefits regarding these conditions, likely due to their anti-inflammatory function.

In a recent meta-analysis published in the online journal PLoS One, scientists reviewed the literature to determine the effect of marine-derived omega-3s on blood levels of several markers of inflammation.

The meta-analysis included 4,601 participants from 68 randomized, controlled trials of healthy subjects, subjects with chronic autoimmune diseases, and subjects with chronic non-autoimmune diseases (ie. cardiovascular disease). Fasting blood levels of the inflammatory markers TNF-a (tumor necrosis factor-alpha), IL-6 (interleukin-6) and CRP (C-reactive protein) were compiled and analyzed. Researchers also separated studies using omega-3s from supplementation as active treatment with those using omega-3s from dietary intake (fish) and included them into different meta-analyses.

A combined analysis of all study subjects revealed a significant link between omega-3 supplementation and decreased blood levels of CRP and IL-6. Among the subjects with chronic non-autoimmune disease, a longer duration of supplementation related to an even greater reduction in blood levels of IL-6 and TNF-a.  A similar finding was observed for IL-6 levels among healthy subjects. Higher dietary intake of omega-3s did result in lower IL-6 levels, but fish intake alone (without supplementation) did not appear to lower CRP or TNF-a.  The benefits of omega-3 supplementation were also more significant in non-obese subjects (BMI <30), particularly in the chronic non-autoimmune disease group.

The results of this study confirm that long-term supplementation of omega-3s from fish oil can effectively lower inflammatory markers and may help reduce the risk of chronic inflammation.

Source:
Li K, Huang et al.  PLoS ONE (2014); 9(2): e88103.

Avocado elerly-manA recent study published in the Journal of the American Medical Association (JAMA) reported on the benefits of vitamin E supplementation in mild to moderate Alzheimer’s disease. Researchers sought to determine if vitamin E, memantine (an ACE inhibitor), or both would slow progression of mild to moderate Alzheimer’s disease (AD).

The double-blind, placebo-controlled, randomized clinical trial involved 613 patients with mild to moderate Alzheimer (AD). Participants were randomized to receive 2,000 international units (IU) of vitamin E, or 20 milligrams of memantine, or a combination of both, or a placebo daily. The average follow-up was 2.3 years.

Patients were analyzed on their capability to perform daily living activities, memory and language, cognitive function, behavioral and psychological issues, and the time needing caregiver assistance. The data was measured and collected at the beginning of the study and every six months during the trial. Over the years of follow-up, scores declined by 3.15 units less in the Vitamin E group compared with the placebo group. In the memantine group, the scores declined 1.98 units less than the decline in the placebo group. Compared to the placebo group, those taking Vitamin E had an average delay in clinical progression of 19% per year, or approximately 6.2 months over the follow-up period.

Patients receiving the vitamin also needed less caregiver assistance in comparison with the placebo group. There was no significant difference in all-cause mortality or safety issues reported between the placebo and Vitamin E groups.

This study showed that high dose Vitamin E (2000 IU) appears to slow functional decline and decrease caregiver burden in patients with mild to moderate Alzheimer’s disease.

Source:
Maurice W. Dysken, MD et al. JAMA 2014; 311(1):33-44.

elerly-womanThere are numerous studies reporting the health benefits of increased fish consumption and higher intakes of the long-chain omega-3 polyunsaturated fatty acids (PUFA) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

The National Heart Foundation of Australia recommends that, to lower the risk of cardiovascular disease, all adult Australians should consume 500 mg/day of combined EPA and DHA through 2–3 serves (150g serve) of oily fish per week and fish oil supplementation. For older adults, the risk of cardiovascular disease is higher; therefore, dietary strategies including increased intake of fish and omega-3 PUFA to reduce risk are necessary.

In the latest cross-sectional survey, 854 Australians (>= 51 yrs of age) were randomly selected to complete either an online survey or telephone interview. The survey included the quantitative fish frequency questionnaire and open- and closed-ended survey questions on demographics and supplement usage.

The survey found that on average:
•             The frequency of finfish/seafood consumption was 1.7 times per week (median intake 173 g);
•             13% never consumed finfish/seafood, or consumed less than once per month;
•             34% ate any type of finfish/seafood more than two times per week;
•             Only 28% consumed just 500 mg long-chain omega-3 PUFA per day from finfish/seafood alone;
•             The mean daily intake of long-chain omega-3 PUFA was 508 mg;

These data indicate that trends in fish intake in Australia are increasing. Although this is encouraging, the current survey still found that only 44% consumed finfish/seafood at least twice per week.  Among older Australians, the current fish consumption is low and many do not meet the current recommendations. Strategies to enhance intake to meet dietary recommendations in this older age group are required.

Source: Grieger, J A et al. Nutrition & Dietetics 2013; 70: 227–235

Athlete_Clint

Previous studies have shown that reducing intake of omega-6 fatty acids and increasing consumption of omega-3 rich fish oil delay the development and progression of prostate cancer. However epidemiologic and observational studies have yielded mixed results. A recent study published in the journal Cancer Prevention Research has found that men with prostate cancer consuming a low fat diet combined with fish oil supplements have a reduced risk of cancer recurrence.

The study included 48 prostate cancer patients assigned either a low-fat diet (15% Kcal from fat) supplemented with fish oil (LFFO), or a high-fat (40% Kcal from fat) western diet (Control). Researchers measured pro-inflammatory compounds in excised prostate cancer tissue and determined the cell cycle progression (CCP) score, which is used to predict cancer recurrence.

Analysis showed that in the LFFO group, there was a decline in the inflammatory marker 15(S)-HETE of 7.2%, but a rise of 24.7% in the control group. Other markers of inflammation (LTB4) were also significantly reduced in the LFFO group but not in the control group. The LFFO group had a significantly lower CCP score versus the control group.

This study found that cancer cell proliferation scores and other markers of inflammation were significantly lower in those who consumed the low-fat fish oil diet compared to men who followed a higher fat Western diet. These results provide strong support for longer term, prospective randomized trials evaluating a low-fat fish oil diet in men with prostate cancer.

Source: Colette Galet et al. Cancer Prev Res; Jan 2014; 7(1):97-104. DOI: 10.1158/1940-6207.CAPR-13-0261.

globalwarming awareness2007